• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing
  3. / U.S. Equity

Analyst Actions -- 9/28/2011

Here are today's top research calls.
By DAVID PELTIER Sep 28, 2011 | 11:15 AM EDT
Stocks quotes in this article: AAPL, COP, JBL, MAS, PRGO, PM, RL, WAG, SYY, CMA, TXX, NVLS., KLAC, ACN, BSX, QCOM, SFD

Accenture estimates, target upped at Goldman

ACN estimates were boosted through 2013, Goldman Sachs said. Company is realizing higher sales and margins. Buy rating and new $62 price target.

-----

Apple estimates boosted at Jefferies

AAPL estimates were upped through 2012, Jefferies said. iPhone strength should offset any iPad cuts. Buy rating and $500 price target.

-----

Apple estimates increased at Needham

AAPL estimates were raised through 2012, Needham said. Mac and iPad sales should drive growth.

-----

Assured Guaranty estimates cut at UBS

AGO estimates lowered through 2011, UBS said.  Lower discount rates on loss reserves.  Maintain $28 price target and Buy rating.

-----

Biomarin Pharmaceuticals upgraded at Deutsche

BMRN was upgraded from Hold to Buy, Deutsche Bank said. $40 price target. Company has a promising pipeline and multiple near-term catalysts.

-----

Boston Scientific target reduced at Goldman

Shares of BSX now seen reaching $6.70, according to Goldman Sachs. Consensus sales expectations appear too high. Neutral rating.

-----

Charles Schwab estimates lowered at JMP

SCHW estimates were cut through 2012, JMP Securities said. Company is realizing lower asset fees and net interest income. Market Perform rating.

-----

Comerica upgraded at Wells

CMA was upgraded from Underperform to Market Perform, Wells Fargo said. Valuation call, as the stock is down 22% over the past 7 weeks.

-----

ConocoPhillips estimates increased at UBS

COP estimates increased through 2012, UBS said.  Shutting down unprofitable refinery.  Maintain $64 price target and Neutral rating.

-----

Coventry Health estimates increased at Morgan Stanley

CVH estimates were raised through 2013, Morgan Stanley said. $39 price target. Company is cutting costs and looking to expand its Medicaid business in Kentucky. Overweight rating.

-----

Equity One estimates cut at UBS

EQY estimates cut through 2012, UBS said.  Reflecting dilution from sale to Blackstone.  Maintain $18 price target and Neutral rating.

-----

Huntington Ingalls rated new Sell at Goldman

HII was initiated with a Sell rating, Goldman Sachs said. $21 price target.  Company is leveraged to a shrinking U.S. defense budget.

-----

Jabil Circuit estimates, target raised at Citigroup

Shares of JBL now seen reaching $22, according to Citigroup.  Estimates also raised on impressive ability to perform in tough macro.  Maintain Hold rating. 

-----

Jabil Circuit estimates, target raised at UBS

Shares of JBL now seen reaching $22, according to UBS.  Estimates also raised on better than expected results in DMS and HVS segments.  Maintain Buy rating. 

-----

KLA-Tencor rated new Neutral at JP Morgan

KLAC was initiated with a Neutral rating, JP Morgan said. Company has solid margins, but exposure to foundry customers. $43 price target.

-----

Lam Research rated new Overweight at JP Morgan

Coverage of LRCX was started with an Overweight rating, JP Morgan said. $56 price target. Company will likely repurchase a lot of its shares.

-----

Masco upgraded at UBS

MAS was upgraded from Sell to Neutral, UBS said.  $7.50 price target.  Impact of weaker macro backdrop already reflected in valuation.

-----

Mead Johnson Nutrition Company downgraded at Citigroup

MJN was downgraded from Buy to Hold, Citigroup said.  $80 price target.  Valuation call as stock has limited upside. 

-----

Mead Westvaco upgraded at JP Morgan

MWV was upgraded from Neutral to Overweight, JP Morgan said. $30 price target. Company is a defensive play an offers a solid dividend yield.

-----

Mylan rated new Hold at Canaccord

MYL was initiated with a Hold rating, Canccord said.  $21 price target.  Near term earnings risk tempers otherwise upbeat view. 

-----

Novellus Systems rated new Overweight at JP Morgan

NVLS was initiated with an Overweight rating, JP Morgan said. $35 price target. Memory business should continue to drive growth and the company will likely return cash to shareholders.

-----

Oneok estimates, target raised at Morgan Stanley

Shares of OKE now seen reaching $82, according to Morgan Stanley. Estimates also increased, given increased growth visibility. Equal-weight rating.

-----

Paccar estimates, target cut at Credit Suisse

PCAR estimates were reduced through 2013, Credit Suisse said. Truck sales should be slower in Europe. Neutral rating and new $39 price target.

-----

Perrigo rated new Hold at Canaccord

PRGO was initiated with a Hold rating, Canaccord said.  $105 price target.  Solid defensive play in a tough tape, but reflected in the stock price already.

-----

Perrigo estimates, target raised at Goldman

Shares of PRGO now seen reaching $110, according to Goldman Sachs. Estimates also increased, as the company is realizing higher margins. Neutral rating.

-----

Perrigo estimates, target raised at UBS

Shares of PRGO now seen reaching $115, according to UBS.  Estimates also raised as double digit earnings growth seems achievable.  Maintain Buy rating.

-----

Philip Morris estimates, target cut at Citigroup

Shares of PM now seen reaching $68, according to Citigroup.  Estimates also lowered on F/X headwinds.  Maintain Hold rating.

-----

Polo Ralph Lauren downgraded at Citigroup

RL was downgraded from Buy to Hold, Citigroup said.  $160 price target.  Ongoing inflation concerns and valuation. 

-----

Qualcomm estimates increased at Sterne Agee

QCOM estimates were raised through 2013, Sterne Agee said. Company is well positioned for customers' new product launches. Buy rating and $67 price target.

-----

Silgan rated new Neutral at JP Morgan

SLGN was initiated with a Neutral rating, JP Morgan said. Valuation call, based on a $44 price target.

-----

Smithfield Foods upgraded at BMO

SFD was upgraded from Market Perform to Outperform, BMO Capital said. $24 price target. Stock is already factoring in lower hog prices.

-----

Sysco rated new Underperform at Credit Suisse

Coverage of SYY was started with an Underperform rating, Credit Suisse said. $23 price target. Growth is maturing and consensus estimates appear to optimistic.

-----

Teva Pharmaceutical rated new Buy at Canaccord

TEVA was initiated with a Buy rating, Canccord said.  $52 price target.  See an inflection point in 2012 on all fronts with sentiment at its lows. 

-----

Texas Instruments estimates upped at Evercore

TXN estimates were boosted through 2012, Evercore Partners said. NSM purchase should add to earnings. Overweight rating and $33 price target.

-----

Walgreens estimates cut at Morgan Stanley

WAG estimates were reduced through 2013, Morgan Stanley said. Express Scripts exit continues to weigh on results. Overweight rating and $45 price target.

-----

Watson Pharmaceuticals rated new Buy at Canccord

WPI was initiated with a Buy rating, Canccord said.  $85 price target.  Solid pipeline with near term catalysts.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.
TAGS: Investing | U.S. Equity

More from U.S. Equity

Let's Update 3 Recent Trades on Meta, Gold and Bumble

Ed Ponsi
Aug 12, 2022 7:00 AM EDT

It's clean-up time.

Poorly Positioned Skeptics Fuel a 'Rampage of Buying'

James "Rev Shark" DePorre
Aug 11, 2022 11:11 AM EDT

This is an extremely tough market for new entries, but that is exactly why it keeps running.

As Charts Improve, Market Data Turn Cautionary

Guy Ortmann
Aug 11, 2022 10:16 AM EDT

After assessing the charts and indicators, here's how we see things going forward.

El Toro Returns, A Wednesday Full of Wow, The Technical Setup, Disney Reports

Stephen Guilfoyle
Aug 11, 2022 7:32 AM EDT

All hail the new bull. Same as the old bull? Not a chance.

2 Attractive Setups I'm Watching as CPI Takes Traders By Surprise

James "Rev Shark" DePorre
Aug 10, 2022 11:16 AM EDT

This is a tough market to chase, but charts should continue to develop

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 10:24 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    To Improve Your Trading and Investing, Spend More ...
  • 08:44 AM EDT PETER TCHIR

    CPI Beats Expectations, But Maybe Not the 'Whisper'?

    Slightly better-than-expected inflation across the...
  • 01:44 PM EDT STEPHEN GUILFOYLE

    This Holding Lights Up With Strong Earnings

    Check out the latest from TheStreet's Stocks Under...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login